Authors: | Kaul, S.; Wojno, K. J.; Stone, S.; Evans, B.; Bernhisel, R.; Meek, S.; D'Anna, R. E.; Ferguson, J.; Glaser, J.; Morgan, T. M.; Lieb, J.; Yan, R.; Cohen, T.; Ehdaie, B. |
Article Title: | Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score |
Abstract: | Aim: To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell cycle risk (CCR) score, a combined clinical and molecular score. Patients & methods: Initial treatment selection (AS vs treatment) and duration of AS were evaluated for men with low-risk prostate cancer according to the CCR score and National Comprehensive Cancer Network guidelines. Adverse events included biochemical recurrence and metastasis. Results: 82.4% (547/664) of men initially selected AS (median follow-up: 2.2 years), 0.4% (2/547) of whom experienced an adverse event. Two-thirds of patients remained on AS for more than 3 years; patient choice was the most common reason for leaving AS. Conclusion: The CCR score may aid in the identification of men who can safely defer prostate cancer treatment. © 2019 Sanjeev Kaul. |
Keywords: | survival; adult; cancer survival; controlled study; aged; major clinical study; cancer risk; cancer patient; follow up; metastasis; cohort analysis; practice guideline; retrospective study; risk assessment; prostate cancer; active surveillance; cancer epidemiology; observational study; biochemical recurrence; clinical outcome; low risk patient; human; male; priority journal; article; clinical cell cycle risk score; molecular score |
Journal Title: | Personalized Medicine |
Volume: | 16 |
Issue: | 6 |
ISSN: | 1741-0541 |
Publisher: | Future Medicine |
Date Published: | 2019-11-01 |
Start Page: | 491 |
End Page: | 499 |
Language: | English |
DOI: | 10.2217/pme-2019-0084 |
PUBMED: | 31483217 |
PROVIDER: | scopus |
PMCID: | PMC7447833 |
DOI/URL: | |
Notes: | Article -- Source: Scopus |